Filgrastim

證據等級: L5

預測適應症: 10 個

Filgrastim: From Neutropenia to Primary Release Disorder of Platelets

One-Sentence Summary

Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF), globally known for stimulating neutrophil production and mobilizing haematopoietic stem cells (a core step in autologous/allogeneic HSCT preparation); it is not currently marketed in Germany. The TxGNN model predicts it may be effective for primary release disorder of platelets, but the supporting evidence base is largely indirect — most identified clinical trials concern general HSCT procedures rather than the disease itself, and only one loosely related publication was found.

Quick Overview

Item	Content
Original Indication	Not available in this evidence pack (drug not marketed in Germany; INN is globally known for chemotherapy-induced neutropenia and stem cell mobilization)
Predicted New Indication	Primary release disorder of platelets
TxGNN Prediction Score	99.998%
Evidence Level	L4
Germany Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (blocking data gap DG002). Based on known pharmacology, filgrastim is a recombinant G-CSF whose core action is stimulating proliferation and differentiation of granulocyte precursors and mobilizing haematopoietic stem cells into peripheral blood — a function widely used clinically to prepare patients for autologous or allogeneic haematopoietic stem cell transplantation (HSCT).

Primary release disorder of platelets (e.g., platelet storage pool disease) is a congenital platelet granule-release defect that, in severe cases, can theoretically be cured by allogeneic HSCT. The proposed mechanistic link is therefore indirect: filgrastim would play a supportive role in stem-cell mobilization prior to transplant, rather than directly correcting the megakaryocyte granule-release defect. No evidence in this evidence pack demonstrates a direct pharmacological effect of G-CSF on megakaryocyte granule release, and this limitation is reflected in the drug's repurposing rationale for this indication.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00281879	Phase 2	Terminated	200	Unrelated donor HSCT for hematological malignancies; G-CSF used for stem cell mobilization/donor lymphocyte infusion support, not disease-specific
NCT02646098	Phase 2	Completed	64	CD34+ selected vs. unselected autologous transplant in lymphoma; relevance graded C — shares G-CSF mobilization process but not directly related to platelet release disorder
NCT04047628	Phase 3	Recruiting	156	Autologous HSCT vs. best available therapy for treatment-resistant multiple sclerosis; relevance graded C — unrelated indication
NCT06859424	Phase 2	Recruiting	358	Post-transplant cyclophosphamide-based GVHD prophylaxis in mismatched unrelated donor PBSC transplant
NCT00245037	Phase 1/2	Completed	147	Non-myeloablative allogeneic HSCT using busulfan/fludarabine/TBI for hematologic malignancies; relevance graded C
NCT05170828	Phase 1	Withdrawn	0	Cryopreserved HLA-mismatched unrelated donor bone marrow transplant with PTCy
NCT01335932	Phase 2	Completed	160	Ganciclovir/valganciclovir for CMV reactivation prevention in lung injury/respiratory failure; not directly related to platelet disorders
NCT00043979	Phase 2	Completed	60	Allogeneic/syngeneic blood stem cell transplant for high-risk pediatric sarcomas
NCT04540120	Phase 2	Terminated	49	Dapansutrile for moderate COVID-19 with cytokine release syndrome; unrelated to platelet release disorders
NCT05436418	Phase 1/2	Recruiting	260	Lowest effective dose of post-transplant cyclophosphamide + sirolimus/MMF for GVHD prophylaxis after PBSC transplant

Note: None of the above trials directly investigate filgrastim's efficacy in primary release disorder of platelets; most are general HSCT-support studies where G-CSF mobilization is a procedural component rather than the study's therapeutic focus.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29770133	2018	Cohort	Frontiers in Immunology	G-CSF mobilization in healthy donors preferentially mobilizes lymphocyte subsets during peripheral blood stem cell collection; describes G-CSF's mobilization mechanism but does not address platelet granule release function

Germany Market Information

Filgrastim currently has no marketing authorization on record in this evidence pack (market status: not marketed, 0 authorizations).

Safety Considerations

Please refer to the package insert for safety information. (TFDA label warnings/contraindications data collection is pending — see data gap DG001.)

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic link between filgrastim and primary release disorder of platelets is indirect (supportive stem-cell mobilization for HSCT, not a direct effect on platelet granule release), and the identified clinical trials are predominantly unrelated general HSCT studies (mostly graded "C" relevance or still pending review) rather than dedicated studies of this indication. Evidence level is L4 (mechanism/preclinical inference only), which does not support progression past initial screening.

To proceed, the following is needed:

TFDA label warnings/contraindications (DG001, blocking — required before any S1 safety evaluation)
Detailed mechanism of action data confirming/refuting a direct effect of G-CSF on megakaryocyte granule release (DG002)
Completion of relevance grading for the remaining "pending" clinical trials
Dedicated preclinical or clinical evidence directly linking filgrastim to platelet release disorder treatment, rather than inferred via general HSCT mobilization use
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.